Physician profile
Catherine Marshall
NPI 1619067477
$3,703.03
in general payments reported to CMS, 2019-2025
31 companies · $911 in 2025
The $911 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $129 · 2021: $230 · 2022: $225 · 2023: $351 · 2024: $1,470 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,732.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $763.98 | 2024-2025 | Qelbree |
| Corium, LLC | $446.08 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $386.87 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $345.61 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $168.58 | 2019-2025 | |
| Intuitive Surgical, INC. | $144.36 | 2019 | |
| Sanofi-Aventis U.S. LLC | $140.22 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.50 | 2020-2021 | |
| Novo Nordisk INC | $132.95 | 2024-2025 | Wegovy, Saxenda |
| Verrica Pharmaceuticals INC. | $120.19 | 2023-2025 | Ycanth |
| Glaxosmithkline, LLC. | $111.11 | 2020-2025 | Bexsero |
| Collegium Pharmaceutical, INC. | $104.78 | 2025 | Jornay Pm |
| Tris Pharma INC | $102.92 | 2021-2025 | Dyanavel Xr, Quillivant |
| Regeneron Healthcare Solutions, INC. | $86.34 | 2024-2025 | Dupixent |
| Cranial Technologies, INC | $81.62 | 2021-2025 | Doc Band |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $54.39 | 2019-2024 | |
| Seqirus USA INC | $54.16 | 2023-2024 | Flucelvax Quadrivalent, Flucelvax |
| Alk-Abello, INC | $45.62 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $32.64 | 2025 | Relexxii |
| Neos Therapeutics, LP | $29.90 | 2025 | Cotempla Xr-Odt |
| Therapeuticsmd, INC. | $28.23 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $27.62 | 2025 | Neffy |
| Mayne Pharma Commercial LLC | $21.46 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.03 | 2024 | Flumist Quadrivalent |
| Noven Therapeutics, LLC | $20.62 | 2025 | Xelstrym |
| Genentech USA, INC. | $19.09 | 2019 | |
| Mylan Pharmaceuticals INC. | $17.26 | 2019 | |
| Hologic Sales and Service, LLC | $15.55 | 2019 | |
| Cognoa, INC. | $15.33 | 2022 | |
| Adlon Therapeutics L.P. | $14.27 | 2019 | |
| Zyla Life Sciences, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.